Clinical trialPhase 2 / Phase 3Recruiting
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 2 / Phase 3
- Status
- Recruiting
- Study type
- Interventional
- Start
- 1 November 2018
- Expected end
- 1 November 2036
- Enrollment
- 200 participants
- Sites
- 1
- Primary outcomes
- Overall survival; Complete response (CR) rate before or at Month 6
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 June 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Builds on itCT-guided intratumoral immunotherapy for advanced solid tumors: a prospective clinical study of safety and systemic ant… DOI 10.3389/fimmu.2026.1869154↗
- Builds on itIntratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept tre… DOI 10.3389/fimmu.2025.1669924↗